ICUS Communications

Category: About ICUS

ICUS WEEKLY NEWS MONITOR
The Weekly News Monitor is a digest of articles and news items about CEUS from all freely available, print and web based media outlets, and it is emailed to over 1250 ICUS members and addressees.    Click here to see all Weekly News Monitors

PRESS RELEASES -- ICUS press releases have been picked up by some 250 news outlets worldwide, including agencies, mainstream media outlets, trade publications and websites.    Click here to see all press Releases

INTERNET
All Weekly News Monitors and press releases are posted on the ICUS website:  www.icus-society.org
In addition, news items and statements regarding specific issues are posted on the home page.

SOCIAL MEDIA
ICUS can be found on both Facebook and Twitter -- links on the website.

Citizen Petition

Category: About ICUS

On behalf of the International Contrast Ultrasound Society (“ICUS”)1, we respectfully submit this Citizen Petition under 21 C.F.R. §§ 10.30 and 201.57(c)(1) to request that the Commissioner of Food and Drugs remove the boxed warnings on ultrasound contrast agents in order to bring the product labeling into line with the current body of scientific research, which now clearly demonstrates the safety and clinical benefits of these radiation-free imaging products.

ICUS members are concerned that current boxed warnings may unduly deter the use of an exceedingly safe, reliable, non-invasive and cost-effective diagnostic imaging tool that does not expose patients to ionizing radiation.

Moreover, given the potential life-saving benefits of ultrasound contrast agents and the potential risks associated their non-use, ICUS believes the boxed warnings are inconsistent with the standards of the Food and Drug Administration (“FDA”) for use of boxed warnings and stand in direct opposition to the FDA’s statutory responsibility to protect promote the health of the American public.

ICUS appreciates that at the time the FDA required the boxed warnings there may have been insufficient data to support clinicians’ positive experience with ultrasound contrast agents, and that the FDA’s decision to add boxed warnings was, at that time, consistent with its regulatory authority and guidance. As advocates for the best interests of patients, ICUS members support legitimate and appropriate safety warnings that reflect currently available data.

However, as new scientific evidence emerges, the key question remains whether the available body of safety data warrants the most serious level of caution -- the boxed warning, with the linchpin being how the risks associated with ultrasound contrast agents relate to their benefits. Framed in this way pursuant to the FDA’s own guidance, the answer is clear: Ultrasound contrast agents are exceedingly safe and do not warrant boxed warnings. Accordingly, ICUS supports the removal of the boxed warning and a significant modification of the warning in order to reflect current scientific data supporting the safety and clinical benefits of ultrasound contrast agents.

 

ICUS Initiatives

Category: About ICUS

ICUS is at the forefront of education, advocacy and communications involving contrast-enhanced ultrasound (CEUS) imaging, which:

  • Improves the accuracy and reliability of conventional ultrasound images in many patients.
  • Reduces the need for redundant, more expensive, and sometimes riskier downstream diagnostic testing.
  • Reduces overall healthcare costs.
  • Does not expose patients to ionizing radiation.
  • Does not utilize contrast agents containing dye, and does not increase the risk of kidney damage.
  • Offers a favorable cost and safety profile at a time of heightened concerns regarding overall health care costs and the cumulative impact of ionizing radiation due to medical diagnostic testing.

To date, key ICUS initiatives have included:  

ICUS GRAND ROUNDS -- ICUS Grand Rounds is an exciting educational initiative that brings ICUS speakers to interested medical centers, physician groups, payors, sonographers, nurses and professional societies. Topics include: CEUS applications, benefits, safety, risks and precautions; How to use CEUS agents and equipment, and how to interpret the scans; Guidelines, coding and payment issues; and other special topics.

FDA BRIEFINGS -- ICUS briefs the staff of the U.S. Food and Drug Administration (FDA) from time to time on new developments in CEUS safety and clinical utility.   In addition, at the request of FDA staff ICUS has prepared and submitted two scientific position papers addressing certain CEUS indications.

REIMBURSEMENT -- ICUS engages with the Centers for Medicare and Medicaid Services (CMS) on reimbursement for use of ultrasound contrast agents based on Medicare HOPPS (hospital outpatient) payment rules.  ICUS also is assessing various issues involving CPT coding.

WEEKLY NEWS UPDATES -- ICUS produces weekly email updates containing articles about the latest developments in the CEUS field.  These ICUS "News Monitors" are emailed each Friday to all ICUS members free of charge.

PRESS RELEASES -- ICUS press releases announce important developments in the CEUS field and are often picked up news media worldwide -- including mainstream media outlets as well as trade publications and websites.  

PUBLICATIONS -- ICUS has authored and co-authored scientific reviews in peer-reviewed journals, thereby expanding the body of CEUS publications.

SUBOPTIMAL ECHO GUIDE -- The ICUS pamphlet on suboptimal echocardiograms is a handy clinical reference tool available at no cost on the ICUS website.

ACCREDITATION -- ICUS worked with the Intersocietal Commission on Accreditation of Echocardiography Laboratories  (ICAEL) in support of the first inclusion of CEUS in new accreditation standards for adult echocardiography laboratories in the U.S.A. Those standards recognize the important role of ultrasound contrast agents in improving the accuracy of diagnostic ultrasound imaging and, therefore, require use of ultrasound contrast agents to enhance images under certain defined circumstances. 

PRACTICE STANDARDS -- ICUS collaborates on the development of practice standards from time to time, including the recent World Federation for Ultrasound in Medicine and Biology (WFUMB) standards governing the use of CEUS in liver imaging.  

COMPARATIVE EFFECTIVENESS TECHNOLOGY ASSESSMENT -- ICUS successfully prompted the inclusion of CEUS in a forthcoming “comparative effectiveness” technology assessment focused on the diagnosis of women with chest pain.  In fact, ICUS was able to assemble scientific data and produce a persuasive document for submission to AHRQ in only three days notice.   

INTERNATIONAL, MULTI-DISCIPLINARY COMMUNICATIONS -- ICUS opens channels of ongoing communication and collaboration across geographical boundaries and medical sub-specialties.  Serving as a unique bridge between diverse constituencies, ICUS makes possible the global cross-fertilization of ideas among CEUS experts in cardiology, radiology, vascular medicine, hepatology, and other imaging fields, including academic researchers, practicing physicians, engineers, industry representatives and others.  

STRATEGIC PLAN -- The ICUS Strategic Plan anticipates further expansion of this work worldwide.

ICUS Leadership Expertise

Category: About ICUS

ICUS Expertise:

About the ICUS Board…

 

Steven B. Feinstein, MD, FACC
Professor of Medicine
Rush University Medical Center
1750 W. Harrison Street, Room 1015 Jelke
Chicago, IL  60612-5020
This email address is being protected from spambots. You need JavaScript enabled to view it.
 

Dr. Feinstein is an NIH-funded investigator, has authored more than 330 scientific publications, and is a frequent journal reviewer and lecturer throughout the United States and Europe. He is internationally recognized for his leadership in the CEUS field and developed the first two FDA-approved ultrasound contrast agents.  His initial work focused on the use of CEUS for cardiac imaging, and has subsequently expanded to include CEUS assessment of vasa vasorem and carotid plaque. Dr. Feinstein also is developing therapeutic applications for CEUS that use ultrasound contrast agents to carry genes to the liver in order to increase the production of de novo HDL.  His clinical practice focuses on preventive cardiology and early diagnosis of cardiac abnormalities.

In addition to serving as Co-president of ICUS, he serves as Program Director of the annual international “Bubble Conference” (Advances in Ultrasound), which he organized 26 years ago.  He also has spoken to the FDA and other government agencies on the superior safety profile of CEUS and its clinical usefulness for detecting heart disease and monitoring therapy.

 

 

Stephanie Wilson, MD, FRCPC
Clinical Professor of Radiology and Gastroenterology - University of Calgary
Radiologist - Foothills Medical Centre
1403 29th Street, NW
Calgary AB Canada
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

First woman president of the Canadian Association of Radiologists.

Dr. Wilson is an internationally recognized expert in the use of CEUS for liver mass characterition and inflammatory bowel disease (IBD).  Her experience in CEUS includes extensive clinical studies performed over the last 13 years, beginning with two single centre phase II trials for evaluation of the use of microbubble contrast agents in Radiology.  These studies resulted in the approval of Definity (Lantheus Medical Imaging, Bellerica, MA) for liver mass characterization in Canada in 2002.  Dr. Wilson shared two Canadian Institute of Health Research (CIHR) grants with Dr Peter Burns for the investigation of contrast agents for radiology practice in Canada.  

Since the introduction of Definity for liver mass characterization in 2002, Dr. Wilson has become the most prominent and busy North American radiologist working routinely with ultrasound contrast agents.  Dr. Wilson and her team perform several thousand examinations yearly, including approved uses for liver imaging and off-label uses involving characterization of masses in all other solid organs and the bowel.  Further, we now recognize the value of CEUS to provide vascular information wherever it is felt that this information might  be contributory to patient management or diagnosis.   Dr. Wilson and her team have Letters of No Objection from Health Canada for our off-label research pursuits related to evaluation of the vasa vasorum in carotid artery plaque and also for monitoring disease activity with CEUS  in patients with inflammatory bowel disease.      

 

 

Petros Nihoyannopoulos, MD, FRCP, FESC, FACC, FAHA
Professor of Cardiology Imperial College London National Heart and Lung Institute
Hammersmith Hospital DuCane Road
London, UK  W12 0NN
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Past President of the British Society of Echocardiography (2001-2003)

Past President of the European Association of Echocardiography of the ESC (2006-2008)

Vice President, ICUS (2010-current)

Member of the Congress Program Committee of the ESC (2007-08) and Chair of the Imaging section.

Chair of Highlights Committee of the ESC (2009-10)

Founder of an annual Master’s degree on Medical Ultrasound at Imperial College London (Echocardiography, Vascular Ultrasound and Obstetrics & Gynecology)

 

Dr. Nihoyannopoulos is a national and international opinion leader in the field of cardiac ultrasound (echocardiography).  He serves as Consultant Cardiologist responsible for managing patients with varied heart conditions admitted under his care. He also serves as head of the echocardiographaphy laboratories at Hammersmith Hospital and head of the teaching program for medical students, research fellows and junior doctors.

Dr. Nihoyannopoulos’ expertise in contrast echocardiography started in 1988, when he first started to use Albunex for improved endocardial border delineation. It was the first commercially available agent for this indication in Europe. Subsequently, in 1993, he led the first multicentre European study looking at the effects of the first saccharide-based transpulmonary contrast agent, Levovist, to study the effects this agent had in enhancing the Doppler signal in various clinical settings; this work led to a publication in JACC (1995; 25: 500-8).  In 1994, Dr. Nihoyannopoulos started using EchoGen in various clinical studies, including renal, hepatic and cardiac enhancement of the Doppler signal and grey-scale sonograms, including stress; this work also led to several publications: Albrecht T, Cosgrove DO, et al. Acad Radiol (1996);3:S198-200, Cosgrove DO,et al. Ultrasound Quarterly (1998);14:66-75] and Calachanis M et al. Cardiovasc Imag (1999);11:123.  Subsequently, in 1996, he instigated a multicentre study using a new ultrasound contrast agent, Infoson, during dobutamine stress echocardiography leading to the first poublication of this agent during stress [Ikonomidis I et al, Coronary Artery Disease (1998);66:229-33].  In 1998, he participated in the first multicentre European trial using a new agent,  NC100100, for the assessment of myocardial perfusion in comparison with MIBI SPECT in a randomised multicentre study, looking at the safety of this agent. [Marwick TH et al. J Am Coll Cardiol (1998);32:1260-69] [Binder et al. Clin Cardiol (1999);22:273-282].  At the same time, he initiated a multicentre study comparing the use of myocardial contrast echocrdiography with NC100100 and Tc-99m SPECT for detecting myocardial perfusion abnormalities in patients with previous myocardial infarction [Jucquois I et al. Heart (2000);83:518-524].

In 1999, on behalf of the British Society of Echocardiography, Dr. Nihoyannopoulos’ work included production of a document on the clinical and economic outcomes in patient assessment using myocardial contrast echocardiography [Shaw LJ, Monaghan MJ, Nihoyannopoulos P. [Heart (1999);Suppl 3, 82:16-2].  By this time, his laboratory was using ultrasound contrast agents routinely for clinical purposes, both for established clinical indications but also off-label for myocardial perfusion during stress. In 2004, he participated in another collaborative study with King’s College London, on the first European contrast agent SonoVueTM [Brown AS, et al. Irish Journal Of Medical Science (2004)173 (1): 13-17]. In 2004, on behalf of the British Society of Echocardiography, he also paprticipated in the publication of procedure guidelines for the Clinical Application of Stress Echocardiography, which highlighted the use of contrast ultrasound [Heart (Suppl)(2004);90:vi23-vi30].  

Dr. Nihoyannopoulos also has played a lead role in the publication of a number of European statements on the use of contrast echocardiography in clinical practice.  Olszewski R et al. Eur J Echocardiogr (2007);8:S13-S23; Rakhit DJ et al. Eur J Echocardiogr (2007);8:S24-S29.  In addition, in 2007, he led the European Committee for Laboratory Standards and published the European Association of Echocardiography recommendations [Nihoyannopoulos P et al. EAE laboratory standards and accreditation. Eur J Echocardiogr (2007);8:80-7.  

In 2006, Dr. Nihoyannopoulos started a program at Imperial College to produce homemade Imperial microbbubles and conjugate them with antibodies to look at myocardial inflammation in mice. This program is now ongoing with extensive collaboration between chemists, physicists, basic scientists and clinicians.

 

 

David Cosgrove, MD, FRCR, FRCP
Imaging Sciences Department Clinical Sciences Centre
Imperial College London
Hammersmith Hospital
Du Cane Road
London W12 0NN, UK
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Michael Main, MD
Medical Director, Echocardiography Laboratory
Mid-America Heart Institute/Saint Luke’s Health System
4330 Wornall Road, #2000
Kansas City, MO  64111
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Brian Fowlkes, PhD
Director, Basic Radiological Sciences Division
Department of Radiology
University of Michigan Health System
3226C Medical Sciences Building I
1301 Catherine Street
Ann Arbor, MI 48109-5667
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Maria Cristina Chammas, MD, PhD
Director - Ultrasound Service
Hospital das Clinicas University of Sao Paolo
Av. Manoel dos Reis Araujo, 453
CEP-04664-000
Sao Paolo - SP - Brazil
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

President-elect of FLAUS (Latin American Federation of ultrasound) for the biennium 2013-2015.

Director of the Department of Ultrasonography, Hospital das Clinicas, University of São Paulo - HC - FMUSP.

Coordinator of the São Paulo Ultrasound Society of Radiology and Diagnostic Imaging (SPR), since 2003.

Ex-Coordinator of the Ultrasound Committee of the Brazilian College of Radiology and Diagnostic Imaging (CBR). (2008-2010).

Member of the Ultrasound Committee of the Brazilian College of Radiology and Diagnostic Imaging. (2005-2008)

Past-Board Reviewer of the journal  "Radiologia Brasileira".

Sociedade Paulista de Radiologia e Diagnóstico por Imagem (SPR).

Sociedade Brasileira de Ultrassonografia (SBUS)

 

Dr. Chammas is a radiologist and is active in internal medicine. Her primary expertise is in the use of CEUS to evaluate the liver, focal kidney diseases, transplants of kidney, liver and pancreas; breast and carotid arteries.

 

Kassa Darge, MD, PhD
Professor of Radiology - Perelman School of Medicine, University of Pennsylvania
Chief, Division of Body Imaging, Department of Radiology - The Children's Hospital of Philadelphia [CHOP]
34th Street & Civic Center Boulevard, Philadelphia, PA 19104-4399, USA
 

Dr. Darge is a nationally and internationally renowned pediatric radiologist and Chief of the Division of Body Imaging at the Department of Radiology of the Children’s Hospital of Philadelphia (CHOP), and Professor of Radiology at the Perelman School of Medicine at the University of Pennsylvania, where he also holds ‘The John Hope Endowed Chair’ for Radiology Faculty Development.  Prior to joining CHOP, Dr. Darge was Professor and Head of the Department of Pediatric Radiology at the University of Wuerzburg, Germany.
 
As Chairman of the Pediatric Contrast-Enhanced Taskforce, Dr. Darge played an important role in the European Federation of Societies of Ultrasound in Medicine (EFSUMB) in contributing the pediatric part of the first CEUS guideline. He is a member of the Pediatric Uroradiology Subcommittees of both the European Society of Pediatric Radiology (ESPR) and the European Society of Urogenital Radiology (ESUR) and plays an active role in putting out the pediatric imaging guidelines regarding CEUS in uroradiology. He has had research collaborations with different ultrasound contrast agent manufacturers and was also involved in the design and introduction of pediatric specific CEUS software for a US company. Dr. Darge has made major contributions to, and was instrumental in, the introduction and advancement of the widespread use of contrast-enhanced voiding urosonography for the diagnosis of vesicoureteric reflux in children in Europe, South America and Asia.
 
As a pediatric radiologist, Dr. Darge has authored 34 scientific publications and has 73 published extracts on pediatric contrast enhanced ultrasound. He is a member of 26 professional societies and an editorial board member or reviewer of 23 scientific journals. He has received several awards including the "Schinz Medal" & "Honorary Membership" from the Swiss Radiological Society, the "Heidi Patriquin International Fellowship for Education Award" from the Society of Pediatric Radiology (SPR), "Contrast Agent Research Award" from the German Radiological Society and "The Schering Prize" from the EFSUMB.
 
Dr. Darge received his M.D. from Addis Ababa University, Ethiopia and his Ph.D. and Dr. Med from Heidelberg University, Germany.  He is also an honorary professor at the Department of Radiology of the Faculty of Medicine at Addis Ababa University, Ethiopia, where he is responsible for the CHOP international pediatric radiology outreach program.  Prior  to his radiology career, Dr. Darge was a research fellow of the World Health Organization (WHO) at the Bernhard-Nocht Institute of Tropical Medicine in Hamburg, Germany.

 

Paul A. Grayburn. MD, FACC
Paul J. Thomas Professor of Medicine
Baylor University Medical Center
Dallas, TX
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Associate Editor, American Journal of Cardiology

Editorial Boards, Circulation, JACC Cardiovascular Imaging, Heart

 

Dr. Grayburn has pioneered the use of ultrasound-targeted microbubble destruction for gene therapy.  This work has resulted in cure of diabetes in rats, and work is now underway in a primate model.  He has served on multiple committees for the American Society of Echocardiography, including the Task Force for Quantitation of Valvular Regurgitation.  He is currently the PI for the MitraClip studies at Baylor Health Care System, and co-investigator for the Cardiothoracic Surgery Network Trials on mitral regurgitation.  His background in both interventional cardiology and echocardiography, including intraoperative TEE during surgical mitral valve repair, give him a unique insight into percutaneous mitral valve therapies.

Dr. Grayburn has published more than 260 papers in the medical literature and has served as Associate Editor of the American Journal of Cardiology since 1997.  He is on the editorial boards of Circulation, JACC: Cardiovascular Imaging, and Heart.  He is currently serving on the Publications Committee for the EVEREST II Trial, and the Core Lab Committee and Steering Committee of the STICH Trial.  He has held a NIH K24 grant for mentoring junior faculty and an R01 grant “Functional MR in Ischemic Cardiomyopathy” for 3D TEE evaluation of the mechanisms of functional MR in the STICH Trial.  He also served as a Core Lab Director for Dr. Christopher Newgard’s program project grant “Novel Therapies for NIDDM.”   

Dr. Paul Grayburn did his general cardiology fellowship under the tutelage of Dr. Anthony N. DeMaria at the University of Kentucky from 1984-1986, followed by a year of interventional cardiology training with Dr. David C. Booth.  In 1988, he was recruited to the University of Texas Southwestern Medical Center by Dr. James T. Willerson, where he served on the faculty for 15 years.  During that time, he was Director of the Echocardiography Laboratories at UT Southwestern, and Chief of Cardiology at the Dallas VA Medical Center, where he also practiced interventional cardiology.  In 2002, Dr. Grayburn moved to Baylor University Medical Center to accept the Paul J. Thomas Chair in Cardiology Research and Education.  Dr. Grayburn is a consultant for Abbott Vascular and receives grant support from the NIH, Abbott Vascular, Medtronic, GE Healthcare, and Guided Delivery Systems.  

 

Wilson Mathias, Jr., MD, FACC
Cardiology, Director - Echocardiography InCor - Heart Institute
The University of Sao Paulo School of Medicine
Av. Dr. Eneas de Carvalho Aguiar, 44
Cerqueira Cesar
Sao Paolo - SP - Brasil 05403-000
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Professor Mark Monaghan, Ph.D., FRCP (Hon), FACC, FESC
Director, Non-Invasive Cardiology
Kings College Hospital Cardiology Department
Denmark Hill, London SE5 9RS, UK
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Pintong Huang, MD, PhD
Prof. and Chief of Department of Ultrasound in Medicine
The Second Affiliated Hospital of Zhejiang University School of Medicine China.
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Fabio Piscaglia, MD
Dept of Digestive Disease and Internal Medicine
General and University Hospital S.Orsola Malpighi
via Albertoni 15
40138 Bologna, Italy
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Dr. Piscaglia heads the Center for Ultrasound in Internal Medicine at the University of Bologna.  He is an internationally-recognized expert in the use of ultrasound and CEUS to detect and evaluate liver tumors and other abnormalities, and frequently publishes and lectures in the field.  He also is president-elect of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB), served as general secretary of the 2000 congress of the World Federation of Ultrasound in Medicine and Biology (WFUMB), and is a peer reviewer for more than 15 scientific journals.  Dr. Piscaglia also organized the Euroson School on CEUS in Liver, Biliary, Pancreatic and Gastrointestinal Disease and has been appointed director of the Clinical School in Liver Imaging of the European Society for the Study of the Liver for 2012.  He also serves on the Editorial Board of Ultraschall / European Journal of Ultrasound.

 

Edward G. Grant MD, FACR
Professor and Chairman Department of Radiology
USC Keck School of Medicine
University Hospital, 1500 San Pablo St.
Los Angeles, CA
This email address is being protected from spambots. You need JavaScript enabled to view it.


Dr Ed Grant represents the USA and Body Imaging. Ed has been an enthusiastic supporter of CEUS for many years and has performed several clinical studies both off label and, more recently, as part of the Bracco multi centre study for characterization of focal liver lesions performed in the USA.

 

 Beverly Gorman, RDCS
ICUS Director - Sonography
IAC Director of Accreditation - Echocardiography
 
Ms. Gorman also is the Director of Accreditation for Echocardiography at the Intersocietal Accreditation Commission.  She has extensive clinical expertise in both adult and pediatric echocardiography, having practiced in both private practice and large hospital settings.    She began her career in 1981 as a medical assistant/cardiac sonographer, training in echo under the supervision of a registered sonographer and a cardiologist. In October 1988, she earned the designation of Registered Diagnostic Cardiac Sonographer (RDCS) in Adult Echocardiography by the ARDMS.

 

Barry Goldberg, MD, FACR
Director, Division of Ultrasound Jefferson Ultrasound Research and Education Institute (JUREI)
Thomas Jefferson University Hospital
132 South 10th Street
763F Main
Philadelphia, PA  19101
This email address is being protected from spambots. You need JavaScript enabled to view it.


Past president, World Federation of Ultrasound in Medicine and Biology

Past president, American Institute of Ultrasound in Medicine

Recipient of Gold Medal for Distinguished Service to Radiology - American Roentgen Ray Society

 

Dr. Goldberg has been at Thomas Jefferson University Hospital as Director, Division of Ultrasound and the Jefferson Ultrasound Research and Educational Institute (JUREI), since 1977.  There, he established the ultrasound division that would grow to become one of the largest ultrasound facilities in the world.

He is a Past President of the American Institute of Ultrasound in Medicine and the World Federation of Ultrasound in Medicine and Biology. He is currently Co-President of the International Contrast Ultrasound Society (ICUS).  His major research efforts have been devoted to the uses of ultrasound contrast agents.  His first paper on this subject was published in 1973 and his research and publications on this subject are ongoing.

He has been named as a Fellow of the American College of Radiology, the American Institute of Ultrasound in Medicine, the Society of Radiologists in Ultrasound, the American Heart Association, the Council of Cardiovascular Radiology, and the American Institute for Medical and Biological Engineering.  The Radiological Society of North America (RSNA) recognized Dr. Goldberg’s research accomplishments when they granted him the Outstanding Researcher Award, and his educational achievements when they granted him the Outstanding Educator award.  The International Society of Radiology honored Dr. Goldberg for his contributions to the advancement of International Radiology by honoring him with its highest honor, the Antoine Beclere Medal.  The American Roentgen Ray Society (ARRS) honored Dr. Goldberg with its highest honor, the Gold Medal for Distinguished Service to Radiology.

Dr. Goldberg has written 319 peer-reviewed papers and 96 chapters.  He has written and/or edited 29 books and has received 148 grants from government, foundations and industry.

 

 

Lennard D. Greenbaum, MD, FACR, FAIUM, FSRU
Co-Director, The Hughes Center for Fetal Diagnostics
Winnie Palmer Hospital for Women & Babies, Orlando Health
83 West Miller Street
Orlando, FL 32806
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Past-President, American Institute of Ultrasound in Medicine (AIUM)

 

Dr. Greenbaum’s major interest is Obstetrical Ultrasound. As a radiologist who performed most aspects of ultrasound for many years, he saw the potential of contrast enhanced ultrasound (CEUS) to improve ultrasound imaging and, therefore, patient care.

During his presidency of the AIUM (2005-2007) he led the organization’s effort to encourage the FDA to approve a non-cardiac indication for an ultrasound contrast agent (UCA). This culminated with the AIUM writing, at the request of the FDA, a guideline for the use of an UCA in the performance of a clinical trial.  (Greenbaum, l; Burns, P; Copel J et al. American Institute of Ultrasound in Medicine Recommendations for Contrast-Enhanced Liver Ultrasound Imaging Clinical Trials. J Ultrasound Med. 2006 June; 26: 705-716.)

 

ICUS in Action

Category: About ICUS

REGULATORY BRIEFINGS (FDA, CMS, AHRQ) -- ICUS has provided professional society briefings, position papers, and scientific materials on the safety and clinical utility of CEUS to the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services Coverage and Analysis Group, and Agency for Health Care Research and Quality.     

REIMBURSEMENT -- ICUS is actively engaged with CMS on issues relating to reimbursement for use of ultrasound contrast agents based on Medicare HOPPS (hospital outpatient) payment rules.  

PRESS RELEASES -- ICUS press releases have been picked up by some 250 news agencies (each)  worldwide, including mainstream media outlets as well as trade publications and websites.  

ICAEL ACCREDITATION -- ICUS worked with the Intersocietal Commission on Accreditation of Echocardiography Laboratories  (ICAEL) in support of the first inclusion of CEUS in new accreditation standards for echocardiography laboratories in the U.S. Those standards now, for the first time, require use of ultrasound contrast agents to enhance images under certain defined circumstances.  This recognizes the important role of ultrasound contrast agents in improving the accuracy of diagnostic ultrasound imaging.

GLOBAL PRACTICE STANDARDS -- ICUS is collaborating on the development of global practice standards for use of CEUS in liver imaging, at the request of the World Federation for Ultrasound in Medicine and Biology (WFUMB).  

COMPARATIVE EFFECTIVENESS TECHNOLOGY ASSESSMENT -- ICUS successfully prompted the inclusion of CEUS in a forthcoming “comparative effectiveness” technology assessment focused on the diagnosis of women with chest pain.  In fact, ICUS was able to assemble scientific data and produce a persuasive document for submission to AHRQ in only three days notice.   

ICUS WEEKLY NEWS MONITORS -- ICUS produces weekly email updates containing articles about the latest developments in the CEUS field.  ICUS Weekly News Monitors are emailed each Friday to all ICUS members free of charge.

ANNUAL “BUBBLE CONFERENCES” -- ICUS sponsors two annual “bubble conferences” focused on advances in the CEUS field.  One is held each Fall in Chicago and the other is held each January in Rotterdam.  Both conferences have expanded opportunities for communication regarding CEUS progress and challenges, networking, collaboration, and energizing the field.

INTERNATIONAL, MULTI-DISCIPLINARY COMMUNICATIONS -- ICUS has opened channels of ongoing communication and collaboration across geographical boundaries and medical sub-specialties.  Serving as a unique bridge between diverse constituencies, ICUS makes possible the global cross-fertilization of ideas among CEUS experts in cardiology, radiology, vascular medicine, hepatology, and other imaging fields, including academic researchers, practicing physicians, engineers, industry representatives and others.  

STRATEGIC PLAN -- The ICUS Strategic Plan anticipates further expansion of this work worldwide.  

ALLIED ORGANIZATIONS -- ICUS has formalized relationships and exchanges liaisons with other professional societies  in order to advance patient interests worldwide.

PRO-BONO SERVICES -- SNR Denton, an international law firm, has determined that ICUS furthers the public interest in safe, cost-effective health care.  Accordingly, ICUS receives numerous services from SNR Denton on a pro bono basis, in accordance with the firm’s commitment to public service.

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

Toshiba Medical logo resized

samsung-logo

siemens-new-original

philips-icus-logo

mindray

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home About ICUS ICUS Board About ICUS